Detects human IL‑22 R alpha 1 in direct ELISAs. In direct ELISAs, less than 1% cross-reactivity with recombinant human IL-20 R beta is observed.
Polyclonal Goat IgG
Chinese hamster ovary cell line CHO-derived recombinant human IL-22 R alpha 1 Pro18-Thr228 Accession # Q8N6P7
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Measured by its ability to neutralize IL‑22-induced IL‑10 secretion in the COLO 205 human colorectal adenocarcinoma cell line. Marehalli, L. et al. (2004) Intl. Immunopharmacol. 4:679. The Neutralization Dose (ND50) is typically 0.2-1 µg/mL in the presence of 1 ng/mL Recombinant Human IL‑22.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
IL‑10 secretion Induced by IL‑22 and Neutralization by Human IL‑22 R alpha 1 Antibody. Recombinant Human IL‑22 (Catalog # 782-IL) stimulates IL‑10 secretion in the COLO 205 human colorectal adenocarcinoma cell line in a dose-dependent manner (orange line), as measured by the Human IL‑10 DuoSet ELISA Development Kit (Catalog # DY217B). IL‑10 secretion elicited by Recombinant Human IL‑22 (1 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL‑22 R alpha 1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2770). The ND50 is typically 0.2‑1 µg/mL.
Preparation and Storage
Reconstitute at 0.2 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-22 R alpha 1
IL-22 receptor, also known as IL-22 R alpha 1 and CRF2-9, is an approximately 65 kDa transmembrane glycoprotein in the type II cytokine receptor family (CRF). IL-22 R alpha 1 contains a 211 amino acid (aa) extracellular domain (ECD) with two fibronectin type III repeats, and a 323 aa cytoplasmic domain. IL-22 R alpha 1 associates with either IL-10 R beta or IL-20 R beta to form receptor complexes with distinct ligand selectivities. IL-10 R beta is a shared subunit of the IL-10, -22, -26, -28, and -29 receptors, while IL-20 R beta is a shared subunit of the IL-19, -20, -22R and -24 receptors (1). IL-22 R alpha 1/IL-10 R beta is an IL-22 responsive receptor (2, 3), and IL-22 R alpha 1/IL-20 R beta is an IL-20 or IL-24 responsive receptor (4, 5). IL-22 R alpha 1 contains cytoplasmic motifs for interactions with signal transduction molecules, but formation of ternary complexes with IL-10 R beta or IL-20 R beta and the respective ligands is required for signal transduction (2, 6). IL-22BP functions as a competitive antagonist by binding
IL‑22 and preventing its association with IL-22 R alpha 1 (7, 9). Even though it is a receptor for interleukins, IL-22 R alpha 1 is not expressed on hematopoietic cells (6, 10, 11). Instead, IL-22 R alpha 1 expression is restricted to epithelial and stromal cells (6, 10‑13). IL-22 R alpha 1 signaling promotes innate immune responses and wound healing at sites of infection and inflammation. This includes upregulation of antimicrobial, acute phase, proinflammatory, and extracellular matrix proteins as well as proteases (3, 11, 13, 14). IL-22 R alpha 1 signaling also promotes downregulation of proteins involved in keratinocyte differentiation (3, 14). Within the ECD, human IL-22 R alpha 1 shares 78%, 76%, and 83% aa sequence identity with mouse, rat, and canine IL-22 R, respectively. It shares 22% - 25% aa sequence identity with the ECDs of other class II receptors IL-10 R, IL-20 R, and IL-28 R.
Langer, J.A. et al. (2004) Cytokine Growth Factor Rev. 15:33.
Xie, M.-H. et al. (2000) J. Biol. Chem. 275:31335.
Boniface, K. et al. (2005) J. Immunol. 174:3695.
Dumoutier, L. et al. (2001) J. Immunol. 167:3545.
Wang, M. et al. (2002) J. Biol. Chem. 277:7341.
Kotenko, S.V. et al. (2001) J. Biol. Chem. 276:2725.
Li, J. et al. (2004) Int. Immunopharmacol. 4:693.
Logsdon, N.J. et al. (2002) J. Interferon Cytokine Res. 22:1099.
Kotenko, S.V. et al. (2001) J. Immunol. 166:7096.
Nagalakshmi, M.L. et al. (2004) Int. Immunopharmacol. 4:577.
Nagalakshmi, M.L. et al. (2004) Int. Immunopharmacol. 4:679.
Aggarwal, S. et al. (2001) J. Interferon Cytokine Res. 21:1047.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.